On May 5, 2025, Marjorie Taylor Greene engaged in a purchase transaction involving shares of AbbVie Inc. (NYSE:ABBV). The transaction amount ranged between $1,001 and $15,000. AbbVie is a major player in the pharmaceutical industry, known for its strong presence in immunology, oncology, and neuroscience. The company has also made significant strides in the aesthetics market through its acquisition of Allergan, the maker of Botox, in 2020.
AbbVie and Johnson & Johnson (JNJ) are two leading U.S. pharmaceutical companies with extensive global operations. Both companies expect 2025 to be a pivotal year, with anticipated increases in sales and profits. AbbVie’s strategic expansion into aesthetics positions it uniquely in the market, while J&J benefits from a diversified business model that includes cardiovascular, metabolic, and infectious disease drugs, as well as a significant presence in the medical devices sector.
The current price of ABBV is $188.67, reflecting an increase of $1.52 or 0.81%. Today, the stock has traded between a low of $186.89 and a high of $189.09. Over the past year, ABBV has seen a high of $218.66 and a low of $153.58. The company’s market capitalization stands at approximately $333.75 billion, indicating its significant size and influence in the pharmaceutical industry.
Today’s trading volume for ABBV is 1,734,317 shares, highlighting active investor interest. As investors consider which company might offer better growth prospects, examining their fundamentals, growth potential, and challenges is crucial. AbbVie’s strategic moves in aesthetics and its strong pipeline in key therapeutic areas make it a compelling option for investors seeking growth opportunities in the pharmaceutical sector.
